# Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis

> **NCT07044115** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 41 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Recombinant Humanized Monoclonal Antibody MIL62 Injection
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07044115
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-26
- **Primary completion:** 2025-01-16
- **Final completion:** 2025-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07044115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07044115, "Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07044115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*